FOR AUTHORS
Search
Search Results
##search.searchResults.foundPlural##
-
CO14 | Inflammation and fibrinolysis biomarkers as predictors of cancer risk in healthy subjects: results from the hypercan study C. Ticozzi1, S. Bolognini1,2, P. Gomez-Rosas1,3, L. Russo1,2, Cj. Tartari1,2, F. Schieppati1,2, G. Sampietro4, L. Barcella1, M. Marchetti1,2, A. Falanga1,2 | 1Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy; 2School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy; 3Maastricht University Medical Center, Cardiovascular Research Institute Maastricht, Maastricht, The Netherlands; 4Unit of Epidemiology and Statistics, ATS Bergamo, Italy
600PDF: 0 -
PO05 | DESIGN, SYNTHESIS, AND BIOLOGICAL EVALUATION OF NOVEL IMATINIB AND NILOTINIB ANALOGUES EXPRESSING ENHANCED ANTIPLATELET AND ANTICANCER ACTIVITIES D. Pantazi1, L. Pechlivani1, A. Kosma1, K. Lalechou1, M.G. Siskos2, D. Alivertis3, A.D. Tselepis1 | 1Atherothrombosis Research Centre, Laboratory of Biochemistry, Department of Chemistry, University of Ioannina, Greece; 2Laboratory of Organic Chemistry, Department of Chemistry, University of Ioannina, Greece; 3Department of Biological Applications and Technology, University of Ioannina, Greece
356PDF: 74 -
Still unmet problems with low molecular weight heparin prophylaxis of venous thromboembolism. An Italian survey
1389PDF: 271HTML: 178Supplementary: 84 -
“Living under the sword of Damocles”: a psychological support project for patients with immune thrombocytopenia and their caregivers
931PDF: 339Appendix A: 124Appendix B: 130 -
CO46 | Comparison of reticulated platelet procoagulant role in liver cirrhosis vs. fibrosis S. Toffanin1, E. Campello1, A. Zanetto2, G. Gagliardi1, A. Napolitano1, E. Stocco1, G. Gobbo1, E. Pinto2, C. M. Radu1, M. Senzolo2, L. Fabris1, P. Simioni1 | 1First Chair of Internal Medicine, Department of Medicine, University-Hospital of Padua Medical School, Padova; 2Department of Surgery Oncology and Gastroenterology, Gastroenterology and Multivisceral Transplant Unit, Padova University Hospital, Padova, Italy
535PDF: 0 -
PO16 | EPIDEMIOLOGY, CLINICAL CHARACTERISTICS, AND OUTCOMES OF PROVOKED AND UNPROVOKED PULMONARY EMBOLISM IN A MULTICULTURAL ISRAELI POPULATION R. Farah1, N.L. Bragazzi2|3|4, H.İ. Ceylan5, Ł. Szarpak6|7|8|9, W. Mahajni1, N. Ashqar1, A. M. Fioretti10, R. Khamisy-Farah11 | 1Internal Medicine B Department, Ziv Medical Center, Azrieli Faculty of Medicine, Bar-Ilan University, Galilee, Safed, Israel; 2Laboratory for Industrial and Applied Mathematics, Department of Mathematics and Statistics, York University, Toronto, Canada; 3Postgraduate School of Public Health, Department of Health Sciences, University of Genoa, Italy; 4UNESCO Chair, Health Anthropology, Biosphere and Healing Systems, University of Genoa, Italy; 5Physical Education and Sports Teaching Department, Faculty of Sports Sciences, Atatürk University, Erzurum, Turkey; 6Department of Clinical Research and Development, LUXMED Group, Warsaw, Poland; 7Institute of Medical Science, Collegium Medicum, The John Paul II Catholic University of Lublin, Lublin, Poland; 8The World Academic Council of Emergency Medicine, Sarasota, FL, USA; 9Henry JN Taub Department of Emergency Medicine, Baylor College of Medicine, Houston, TX, USA; 10Cardio-Oncology Unit, IRCCS Istituto Tumori “Giovanni Paolo II”, Bari, Italy; 11Clalit Health Service, Azrieli Faculty of Medicine, Bar-Ilan University, Galilee, Safed, Israel
282PDF: 70 -
PO13 | Monitoring of anti-factor XA activity levels in patients treated with direct oral anticoagulants and concomitant tyrosine kinase inhibitors agents: a monocentric experience E. Santacroce1,2, C. Santoro1, E. Baldacci1, S. Ligia1, R. Mormile1, M. Biglietto1, M. Totaro1, F. R. Mauro1, M. Breccia1, A. Chistolini1 | 1Department of Translational and Precision Medicine, Haematology, Sapienza University of Roma; 2Department of Clinical and Molecular Medicine, Sapienza University of Roma, Italy
579PDF: 0 -
CO08 | The utility of urine qualitative assessment for direct oral anticoagulants in routine clinical practice F. Schieppati1,2, P. Gomez-Rosas1,3, C. Ambaglio1, V. Brusegan1, Oc. Cretu1,2, E. Galimberti1, F. Zunino1, L. Barcella1, J. Harenberg4,5, A. Falanga1,2, M. Marchetti1,2 | 1Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy; 2School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy; 3Maastricht University Medical Center, Cardiovascular Research Institute Maastricht, Maastricht, The Netherlands; 4Ruprecht Karls University of Heidelberg, Germany; 5Germany DOASENSE GmbH, Heidelberg, Germany
680PDF: 0 -
PO57 | A NOVEL RISK ASSESSMENT MODEL FOR CANCER DETECTION WITHIN ONE YEAR AFTER INCIDENT VENOUS THROMBOEMBOLISM C. Antoun1, J. Hansen1|3, S. Brækkan1|3, C. Langholm1, N. Eide1, V. Morelli1|3, K. Hveem2 | 1Department of Clinical Medicine, UiT The Arctic University of Norway, Tromsø; 2HUNT Center for Molecular and Clinical Epidemiology, Norwegian University of Science and Technology, Trondheim; 3Thrombosis Research Center, Division of Internal Medicine, University Hospital of North Norway, Tromsø, Norway
327PDF: 86 -
CO44 | First interlaboratory validation workshop of immunofluorescence microscopy on the peripheral blood smear for recognizing patients with inherited platelet disorders C. Zaninetti1, L. Bury2, V. Bozzi3, A. Zamora-Cánovas4, K. Althaus5, G. Uzun5, S. Brown6, A. Norman6, D. Faille7, A. Stepanian8, C. Freyer1, L. Kager9, T. Bakchoul5, A. Pecci3, P. Gresele2, T. Thiele1, J. Rivera4, A. Greinacher1 | 1Institut für Immunologie und Transfusionsmedizin, Universitätsmedizin Greifswald, Germany; 2Department of Medicine, Section of Internal and Cardiovascular Medicine, University of Perugia, Italy; 3Department of Internal Medicine, University of Pavia, Italy; General Medicine 1, IRCCS Policlinico San Matteo Foundation, Pavia, Italy; 4Servicio de Hematología, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonacio´n, Universidad de Murcia, Spain; 5Institute for Clinical and Experimental Transfusion Medicine, University Hospital of Tuebingen, Germany; Center for Clinical Transfusion Medicine, Tuebingen, Germany; 6Centre for Children’s Health and Research CCHR, South Brisbane, Australia; 7Laboratoire d’Hématologie, Assistance Publique Hôpitaux de Paris, Hôpital Bichat-Claude-Bernard, Paris, France; 8AP-HP, Service d’Hématologie Biologique, Hôpital Lariboisière, Paris Cité University, Paris, France; 9St. Anna Kinderspital, Universitätsklinik für Kinder- und Jugendheilkunde der Medizinischen Universität Wien, Austria
535PDF: 0 -
PO14 | SYMPTOM BURDEN IN PATIENTS WITH CANCER AND THROMBOEMBOLISM: A POPULATION-BASED MATCHED COHORT STUDY D. Siegal1|2, Z. O’Neill1|2, L. Nguyen3, N. Liu3, M. Carrier1|2, R. Sutradhar3|4 | 1Ottawa Hospital Research Institute, Ottawa; 2Department of Medicine, University of Ottawa, Ottawa; 3ICES, Toronto, Canada; 4Dalla Lana School of Public Health, University of Toronto, Toronto, Canada
315PDF: 70 -
PO02 | Pregnancy and delivery in women with hemophilia and carriers are still challenging: a ten years analysis from The Italian Association of Hemophilia Centers (AICE) M. Napolitano1, M. Mattana2, C. Cammarata1, M. Leotta3, S. Linari4, M.E. Mancuso5, G. F. Rivolta6, C. Santoro7, L. Valdrè8, R.C. Santoro3, S. Siragusa1 | 1Department of Health Promotion, Mother and Child Care, Internal Medicine and Med, Palermo; University of Palermo, Italy; 2Department of Precision Medicine in Medical, Surgical and Critical Care “Me. Pre. Cc”, University of Palermo; 3Hemostasis and Thrombosis Unit, Azienda Ospedaliera Universitaria Dulbecco, Catanzaro; 4Center for Bleeding Disorders, Careggi University Hospital, Firenze; 5Center for Thrombosis and Hemorrhagic Diseases, IRCCS Humanitas Research Hospital, Rozzano, Milan; 6Regional Reference Center for the Treatment of Congenital Hemorrhagic Diseases, Parma University Hospital, Parma; 7Hematology, University Hospital Policlinico Umberto I, Roma; 8Inherited Bleeding Disorders Unit, IRCCS AOUBO, Bologna, Italy
629PDF: 0 -
PO31 | MIGRATORY SUPERFICIAL THROMBOPHLEBITIS REFRACTORY TO APIXABAN IN A PATIENT WITH LUNG ADENOCARCINOMA I. Goldberg1|2, P. Raanani1|2|3, G. Spectre1|2 | 1Institute of Hematology, Beilinson Hospital, Rabin Medical Center, Petah Tikva, Israel; 2Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel; 3Felsenstein Medical Research Center, Rabin Medical Center, Petah Tikva, Israel
330PDF: 75 -
CS04 | Association between elevated plasma levels of tissue plasminogen activator and occult cancer risk: a nested case-cohort analysis in 10,294 healthy subjects S. Bolognini1,2, C. Ticozzi1, P. Gomez-Rosas1,3, L. Russo1,2, Cj. Tartari1,2, F. Schieppati1,2, G. Sampietro4, L. Barcella1, M. Marchetti1,2, A. Falanga1,2 | 1Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy; 2School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy; 3Maastricht University Medical Center, Cardiovascular Research Institute Maastricht, The Netherlands; 4Unit of Epidemiology and Statistics, ATS Bergamo, Italy
620PDF: 0 -
CO39 | Artificial intelligence in hemophilia management: challenging the need for experts G. Sottilotta1, D. Megalizzi1, F. Luise2 | 1UOSD Microcitemie - Emostasi e Trombosi. Grande Ospedale Metropolitano Bianchi-Melacrino-Morelli, Reggio Calabria; 2Laboratorio Analisi, Grande Ospedale Metropolitano Bianchi-Melacrino-Morelli, Reggio Calabria, Italy
555PDF: 0
